Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 46124U107 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Invus Global Management, LLC
13G/A
|
10.6% |
7/31/2025
Event 6/30/2025
|
||
| Invus Public Equities, L.P. | 10.6% | |||
| Invus Public Equities Advisors, LLC | 10.6% | |||
| Invus Global Management, LLC | 10.6% | |||
| Siren, L.L.C. | 10.6% | |||
| Raymond Debbane | 10.6% | |||
|
Sofinnova Crossover I
13G/A
|
8.6% |
2/17/2026
Event 12/31/2025
|
||
| Sofinnova Crossover I SLP | 5.6% | |||
| Sofinnova Crossover II SLP | 3.1% | |||
| Sofinnova Partners SAS, a French corporation | 8.6% | |||
| Antoine Papiernik | 8.6% | |||
| Cedric Moreau | 8.6% | |||
| Kinam Hong | 8.6% | |||
| Joseph Anderson | 8.6% | |||
| Jacques Theurillat | 5.6% | |||
|
Andera Partners
13G/A
|
7.7% |
2/17/2026
Event 12/31/2025
|
||
| Andera Partners | 7.7% | |||
| BioDiscovery 6 FPCI | 7.7% | |||
| Stephane Bergez | 7.7% | |||
| Francois Xavier Mauron | 7.7% | |||
|
Samsara BioCapital, L.P.
13D/A
|
7.4% |
11/19/2025
Event 11/17/2025
|
||
| Samsara BioCapital, L.P. | 4.5% | |||
| Samsara BioCapital GP, LLC | 4.5% | |||
| Samsara Opportunity Fund, L.P. | 2.8% | |||
| Samsara Opportunity Fund GP, LLC | 2.8% | |||
| Srinivas Akkaraju | 7.4% | |||
|
Yiheng Capital Management, L.P.
13G/A
|
5.5% |
11/13/2025
Event 9/30/2025
|
||
| Yiheng Capital Partners, L.P. | 5.5% | |||
| Yiheng Capital, LLC | 5.5% | |||
| Yiheng Capital Management, LP | 5.5% | |||
| Yuanshan Guo | 5.5% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (5) | ||||
|
Biotechnology Value Fund L P
13D/A
|
4.99% |
11/19/2025
Event 11/17/2025
|
||
| Biotechnology Value Fund L P | 2.9% | |||
| BVF I GP LLC | 2.9% | |||
| Biotechnology Value Fund II LP | 1.7% | |||
| BVF II GP LLC | 1.7% | |||
| Biotechnology Value Trading Fund OS LP | 0.2% | |||
| BVF Partners OS Ltd. | 0.2% | |||
| BVF GP Holdings LLC | 4.7% | |||
| BVF Partners L P/IL | 4.99% | |||
| BVF Inc/IL | 4.99% | |||
| Lampert Mark N | 4.99% | |||
|
Perceptive Advisors LLC
13G/A
|
4.99% |
11/14/2025
Event 9/30/2025
|
||
| Perceptive Advisors LLC | 4.99% | |||
| Joseph Edelman | 4.99% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 4.99% | |||
|
New Enterprise Associates 17, L.P.
13D/A
|
4.9% |
4/1/2026
Event 3/30/2026
|
||
| New Enterprise Associates 17, L.P. | 4.9% | |||
| NEA Partners 17, L.P. | 4.9% | |||
| Nea 17 GP, LLC | 4.9% | |||
| Growth Equity Opportunities 18 VGE, LLC | 4.9% | |||
| NEA 18 Venture Growth Equity, L.P. | 4.9% | |||
| NEA Partners 18 VGE, L.P. | 4.9% | |||
| Nea 18 Vge GP, LLC | 4.9% | |||
| Forest Baskett | 4.9% | |||
| Ali Behbahani | 4.9% | |||
| Carmen Chang | 4.9% | |||
| Anthony A. Florence, Jr. | 4.9% | |||
| Mohamad H. Makhzoumi | 4.9% | |||
| Edward T. Mathers | 4.9% | |||
| Scott D. Sandell | 4.9% | |||
| Paul Walker | 4.9% | |||
| Rick Yang | 4.9% | |||
| Pierre Broqua 13G/A | 4.3% |
2/14/2025
Event 12/31/2024
|
||
|
Deep Track Capital, LP
13G/A
|
3.8% |
5/15/2026
Event 3/31/2026
|
||
| Deep Track Capital, LP | 3.8% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 3.8% | |||
| David Kroin | 3.8% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 18.6 k | $68.6 k |
| 2026 Q2 | 89 | 87.3 M | $326 M |
| 2026 Q1 | 65 | 52.4 M | $290 M |
| 2025 Q4 | 53 | 46.7 M | $217 M |
| 2025 Q3 | 15 | 5.11 M | $29.4 M |
| 2025 Q2 | 13 | 4.93 M | $15.7 M |
| 2025 Q1 | 9 | 4.86 M | $12.2 M |
| 2024 Q4 | 8 | 5.45 M | $11.7 M |
| 2024 Q3 | 8 | 4.85 M | $9.06 M |
| 2024 Q2 | 9 | 4.85 M | $14.5 M |
| 2024 Q1 | 11 | 4.86 M | $17.6 M |
| 2023 Q4 | 11 | 4.87 M | $21.9 M |
| 2023 Q3 | 9 | 4.86 M | $20.6 M |
| 2023 Q2 | 10 | 4.83 M | $19.5 M |
| 2023 Q1 | 10 | 5.13 M | $18.3 M |
| 2022 Q4 | 8 | 4.81 M | $21.9 M |
| 2022 Q3 | 9 | 8.93 M | $33.1 M |
| 2022 Q2 | 11 | 9.11 M | $51.8 M |
| 2022 Q1 | 11 | 3.93 M | $45.0 M |
| 2021 Q4 | 11 | 3.76 M | $51.3 M |
| 2021 Q3 | 13 | 3.71 M | $52.5 M |
| 2021 Q2 | 15 | 1.56 M | $21.3 M |
| 2021 Q1 | 15 | 1.62 M | $23.8 M |
| 2020 Q4 | 16 | 2.73 M | $39.2 M |
| 2020 Q3 | 18 | 4.02 M | $47.5 M |